AbbreviationsGFRGlomerular filtration rateRPSRetroperitoneal sarcomaCKDChronic kidney diseaseINTRODUCTIONRetroperitoneal sarcomas (RPS) are relatively uncommon, representing less than 1% of annual cancer incidences. Current available chemotherapy regimens and radiation therapy for RPS have shown questionable survival benefit. Surgery remains the cornerstone of treatment for these malignancies with a R0 resection offering the only chance for cure.Controversy exists surrounding the ideal surgical management of RPS, specifically the indications for nephrectomy during en‐bloc resection. Five‐year local recurrence rates have been reported to be 31–63%, stressing the importance of a complete resection and its associated increased survival. Given this, some authors argue for an aggressive compartmental operative approach that often involves nephrectomy, as past evidence has shown improved loco‐regional control with this approach.Other authors contend that surgical strategy should be individualized based on histology and the relationship the tumor has within the anatomically complex retroperitoneal cavity. They cite the potential morbidity and mortality associated with an aggressive multi‐visceral approach to RPS. In particular, they argue there is a potential long‐term risk of chronic kidney disease (CKD) associated with those patients undergoing nephrectomy as well as the limitations this may impose on adjuvant treatment. Few would argue against a nephrectomy as part of en‐bloc RPS resection with
Journal of Surgical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud